Current methods in translational cancer research

Recent developments in pre-clinical screening tools, that more reliably predict the clinical effects and adverse events of candidate therapeutic agents, has ushered in a new era of drug development and screening. However, given the rapid pace with which these models have emerged, the individual merits of these translational research tools warrant careful evaluation in order to furnish clinical researchers with appropriate information to conduct pre-clinical screening in an accelerated and rational manner. This review assesses the predictive utility of both well-established and emerging pre-clinical methods in terms of their suitability as a screening platform for treatment response, ability to represent pharmacodynamic and pharmacokinetic drug properties, and lastly debates the translational limitations and benefits of these models. To this end, we will describe the current literature on cell culture, organoids,in vivomouse models, andin silicocomputational approaches. Particular focus will be devoted to discussing gaps and unmet needs in the literature as well as current advancements and innovations achieved in the field, such as co-clinical trials and future avenues for refinement.

Automated summary

Recent advancements in pre-clinical screening tools have led to a new era in drug development, with more accurate prediction of clinical effects and adverse events for candidate therapeutic agents. However, careful evaluation is necessary to determine the individual merits of these translational research tools to provide appropriate information for clinical researchers to conduct pre-clinical screening in an accelerated and rational manner.